| Sign In to gain access to subscriptions and/or personal tools. |
DOI: 10.1177/1352458506070943 © 2006 SAGE Publications Multiple sclerosis conference synopsis and discussion: cellular therapy for treatment of autoimmune diseases (October 2005)Department of Neurology, City of Hope National Medical Center, Duarte, CA, USA, hopenshaw{at}coh.org
Blood and Bone Marrow Transplant Program, The Ottawa Hospital, Ottawa, Canada
McConnell Brain Imaging Centre, Montreal Neurological Institute and Hospital, Montreal, Canada
Unidade de Neurologia Clinica, Curitiba, Brazil
Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
Department of Neurology, Johns Hopkins Hospital, Baltimore, MD, USA
Department of Neurology, Harvard University, Boston, MA, USA
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA
Bone Marrow Transplantation Unit, Careggi Hospital, University of Florence, Italy At a conference held in October 2005, participants presented studies on high dose immunosuppression with hematopoietic cell transplant (HCT) for multiple sclerosis (MS), including neuroimmuno-logical and magnetic resonance imaging (MRI) mechanistic approaches, clinical registry reports, and ongoing or newly-designed protocols. A discussion panel considered questions on how to define success, timing of controlled clinical trials, difficulty in patient recruitment, and future direction of high dose therapy.
Key Words: cyclophosphamide • hematopoietic cell transplantation • immunosuppression • multiple sclerosis References
  CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
 |
|
Sign In to gain access to subscriptions and/or personal tools.
